Svédország - svéd - Läkemedelsverket (Medical Products Agency)

orifarm ab - ciklosporin - kapsel, mjuk - 100 mg - propylenglykol hjälpämne; glycerol 85% hjälpämne; sorbitol hjälpämne; etanol, vattenfri hjälpämne; makrogolglycerolhydroxistearat hjälpämne; ciklosporin 100 mg aktiv substans

Svédország - svéd - Läkemedelsverket (Medical Products Agency)

taw pharma (ireland) ltd - amlodipinbesilat - oral suspension - 1 mg/ml - amlodipinbesilat 1,386 mg aktiv substans

Európai Unió - svéd - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiska medel - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. för vidare information om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. för ytterligare information om her2-status, se avsnitt 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).

Svédország - svéd - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - atorvastatinkalcium, amorft - filmdragerad tablett - 10 mg - atorvastatinkalcium, amorft 10,36 mg aktiv substans; mannitol hjälpämne - atorvastatin

Svédország - svéd - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - atorvastatinkalcium, amorft - filmdragerad tablett - 20 mg - mannitol hjälpämne; atorvastatinkalcium, amorft 20,72 mg aktiv substans - atorvastatin

Svédország - svéd - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - atorvastatinkalcium, amorft - filmdragerad tablett - 40 mg - atorvastatinkalcium, amorft 41,44 mg aktiv substans; mannitol hjälpämne - atorvastatin

Svédország - svéd - Läkemedelsverket (Medical Products Agency)

doc generici srl - duloxetinhydroklorid - enterokapsel, hård - 30 mg - natriumlaurilsulfat hjälpämne; sockersfärer hjälpämne; duloxetinhydroklorid 33,678 mg aktiv substans; sackaros hjälpämne - duloxetin

Svédország - svéd - Läkemedelsverket (Medical Products Agency)

pensa pharma ab - duloxetinhydroklorid - enterokapsel, hård - 30 mg - propylenglykol hjälpämne; natriumlaurilsulfat hjälpämne; sackaros hjälpämne; sockersfärer hjälpämne; duloxetinhydroklorid 33,678 mg aktiv substans - duloxetin

Svédország - svéd - Läkemedelsverket (Medical Products Agency)

towa pharmaceutical europe s.l. - duloxetinhydroklorid - enterokapsel, hård - 30 mg - natriumlaurilsulfat hjälpämne; duloxetinhydroklorid 33,678 mg aktiv substans; sackaros hjälpämne; sockersfärer hjälpämne - duloxetin

Svédország - svéd - Läkemedelsverket (Medical Products Agency)

towa pharmaceutical europe s.l. - duloxetinhydroklorid - enterokapsel, hård - 60 mg - sackaros hjälpämne; duloxetinhydroklorid 67,356 mg aktiv substans; sockersfärer hjälpämne; natriumlaurilsulfat hjälpämne - duloxetin